Personal History Of Endometrial Cancer Icd 10

Personal History Of Endometrial Cancer Icd 10

The code you're looking for is Z85.42 — Personal history of malignant neoplasm of endometrium. It sits in the Z chapter of ICD-10, which handles factors influencing health status and contact with health services rather than active disease. That distinction matters more than most people realize when they first start working with this code. This code applies when a patient has a prior history of endometrial cancer and the condition is no longer present or being actively treated. It signals to payers and registries that there's a documented history of the disease, but it is not a current malignancy. If the patient is still undergoing treatment for endometrial cancer, you'd use C54.1 instead. Mixing those two up is one of the more common billing errors I see come through my inbox, usually during transitions of care when a patient moves from oncology follow-up back to primary care. I also want to clarify what falls outside the scope of this code. A family history of endometrial cancer would be Z80.4, not Z85.42. These are often confused by coders who aren't tracking whether the history is personal or familial. The distinction carries weight for screening recommendations and genetic counseling referrals, so it's not just a coding nitpick.

How It Works In Practice

When I'm reviewing a chart for a patient with prior endometrial cancer who is now presenting for routine surveillance or an unrelated complaint, Z85.42 goes on as a secondary diagnosis. The primary reason for the encounter drives the first-listed code. This became especially relevant after the 2023 ICD-10-CM guidelines clarified that history codes should always follow the reason for the current visit unless the history itself is the focus of the encounter. Here's a scenario that tripped me up early in my career. A patient with a remote history of endometrial cancer presented with abdominal pain and imaging revealed a new mass. The oncologist was fairly certain it was a recurrence and started the patient on chemotherapy. My initial code assignment was Z85.42 because that's what the chart said on the history section. The DRG grouper flagged it during an audit because the active treatment meant the primary malignancy code should have been used instead. The workaround was straightforward once I caught it — verify active treatment status against the most recent oncology note and imaging results before finalizing the code. I now make it a habit to cross-reference the active problem list against any history codes in the same encounter.

Pitfalls That Cost Money

One thing nobody warns you about is the interaction between Z85.42 and Lynch syndrome coding. Patients with endometrial cancer who also carry a MLH1, MSH2, MSH6, or PMS2 mutation get additional Z codes for the genetic predisposition. I recently reviewed a case where the coder included Z85.42 and a BRCA code simultaneously. BRCA mutations relate to breast and ovarian cancer risk, not endometrial. The correct companion code for Lynch-related endometrial cancer history is Z15.02, not a BRCA code. Using the wrong genetic code can trigger a medical necessity review that stalls reimbursement for months. Another counter-intuitive detail: Z85.42 does not exempt a patient from breast cancer screening. The code specifically covers endometrial history only. Some providers mistakenly assume a blanket cancer history code removes the need for age-appropriate preventive coding. It doesn't. You still need the appropriate screening codes for whatever screenings are due based on the patient's current risk profile.

Limitations And When It Fails

The code has a narrow application window. Once a patient with prior endometrial cancer develops a new primary malignancy, Z85.42 becomes a secondary history code at best. If the new cancer is metastatic disease from the original endometrial primary, you code the current metastatic site, not a history code. The boundary between metastasis and new primary is where audits concentrate, and it's not always clear-cut histologically. Additionally, Z85.42 is not valid for use as a principal diagnosis on its own in inpatient settings under most payer policies. Some smaller Medicare Advantage plans have been known to deny claims where this is the only diagnosis listed, even for encounters that are legitimately focused on surveillance. The fix is always to attach the surveillance encounter code — Z08 for follow-up examinations after treatment for malignant neoplasms — as the primary code with Z85.42 secondary. That combination handles the vast majority of denial scenarios I encounter.

What To Check Before Submitting

Confirm the original cancer was truly endometrial and not of another uterine subsite. Cervical, ovarian, and vulvar cancers each have their own Z85 codes. The pathology report from the original treatment is the document that settles any ambiguity. Second, verify the patient has no current active disease. Third, check whether the encounter supports a separate screening or surveillance code alongside Z85.42. Those three checks take about two minutes and prevent probably the majority of the edit rejections I deal with on a weekly basis.